Immuneering’s (IMRX) “Buy” Rating Reiterated at Chardan Capital

Chardan Capital restated their buy rating on shares of Immuneering (NASDAQ:IMRX) in a research report report published on Wednesday,Benzinga reports. The brokerage currently has a $13.00 price objective on the stock.

IMRX has been the topic of several other reports. Needham & Company LLC reaffirmed a “buy” rating and issued a $15.00 target price on shares of Immuneering in a research note on Tuesday. Morgan Stanley lowered Immuneering from an “equal weight” rating to an “underweight” rating in a research report on Friday, December 13th. One analyst has rated the stock with a sell rating, three have given a hold rating and four have assigned a buy rating to the company’s stock. According to MarketBeat.com, the stock has an average rating of “Hold” and an average price target of $12.80.

Immuneering Stock Performance

Immuneering stock opened at $2.00 on Wednesday. The stock has a market cap of $62.10 million, a P/E ratio of -1.02 and a beta of -0.34. Immuneering has a fifty-two week low of $1.00 and a fifty-two week high of $7.68. The firm’s fifty day moving average price is $2.04 and its 200-day moving average price is $1.77.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently bought and sold shares of IMRX. Marshall Wace LLP bought a new stake in Immuneering during the second quarter valued at approximately $492,000. Renaissance Technologies LLC bought a new position in Immuneering in the 2nd quarter worth $447,000. Acadian Asset Management LLC bought a new stake in Immuneering during the second quarter valued at about $67,000. Tidemark LLC bought a new position in shares of Immuneering in the third quarter worth about $129,000. Finally, Point72 Asia Singapore Pte. Ltd. purchased a new position in shares of Immuneering during the 2nd quarter valued at about $44,000. 67.65% of the stock is owned by hedge funds and other institutional investors.

About Immuneering

Immuneering Corporation, a clinical-stage oncology company, engages in the development of medicines for broad populations of cancer patients. Its lead product candidates include IMM-1-104, a dual-MEK inhibitor currently under Phase 1/2a clinical trial to treat patients with cancer, including pancreatic, melanoma, colorectal, and non-small cell lung cancer caused by mutations of RAS and/or RAF; and IMM-6-415 is in Investigational New Drug application to treat solid tumors.